The AstraZeneca share price is rising fast. Here’s what I’d do now

FTSE 100 pharmaceuticals giant AstraZeneca turned in a good set of results. Is it time to buy right now?

| More on:

The content of this article was relevant at the time of publishing. Circumstances change continuously and caution should therefore be exercised when relying upon any content contained within this article.

You’re reading a free article with opinions that may differ from The Motley Fool’s Premium Investing Services. Become a Motley Fool member today to get instant access to our top analyst recommendations, in-depth research, investing resources, and more. Learn More.

The FTSE 100 pharmaceuticals giant AstraZeneca (LSE: AZN) share price was a big gainer yesterday, rising by 5.5% from the day before as it reported a healthy set of results. Its share price is now close to all-time highs, raising the question – Is this a good time to buy AZN?

Expensive but worthy

I find it helpful to look at the price-to-earnings ratio (P/E) when share prices are rising to get a sense of how expensive the stock really is. From the looks of it, AZN sure is highly priced. Its 12-month trailing P/E is almost 43x compared to 19x for another FTSE 100 pharmaceuticals peer GlaxoSmithKline (GSK). Not to undermine GSK’s value, but I think this is a case of investors putting a premium on AZN rather than a one-off spike in its P/E, considering that it’s been maintained for some time now.

It was my top share for May, after it reported a good set of numbers and my sense was that it would rise from there on. From the time the article was published to now, the share price is up 31% and interestingly enough, the P/E is actually marginally lower than the 45x seen then. As an investor, this tells me that there are capital gains to be made even if the ratio is high, instructive as it is. Also, a high ratio doesn’t indicate that the share price will come off soon. In other words, don’t let a high P/E deter you right now because there are enough reasons that still make AZN attractive.  

Safe haven

It’s a big pharmaceuticals company in an economic environment that continues to look uncertain. A number of other defensive shares have also seen a great run-up in share prices in recent years and AZN is no exception. Its international focus also helps, since it’s not entirely vulnerable to the UK’s fortunes. In the latest earnings release, CEO Pascal Soriot noted “impressive results” in international markets like China, the US and Japan.

Performance boost

Besides this, yesterday’s results showed an 18% increase in product sales at constant exchange rate and core operating profit grew by 41% in the third quarter of 2019. The numbers look good on a year-to-date basis too. I also like that AZN has actually upgraded its sales guidance for the second straight quarter, which basically means that it is expected to continue performing going forward.

Coming back to the original question – should I buy AZN shares now, even with the price rise? I reckon that its share price will rise higher over time if things continue to go the way they are right now. Since we at the Motley Fool are concerned with long-term investments, now is as good a time as any other to buy the share. As is the nature of share prices, there will most likely be short-term dips in the near future, and that should be an opportunity to buy more of AZN. But some can be bought right away, I believe.

Manika Premsingh has no position in any of the shares mentioned. The Motley Fool UK has recommended AstraZeneca. Views expressed on the companies mentioned in this article are those of the writer and therefore may differ from the official recommendations we make in our subscription services such as Share Advisor, Hidden Winners and Pro. Here at The Motley Fool we believe that considering a diverse range of insights makes us better investors.

More on Investing Articles

UK financial background: share prices and stock graph overlaid on an image of the Union Jack
Investing Articles

Why did Raspberry Pi shares just jump 35%?

Raspberry Pi shares have been in the doldrums in the past 12 months. But is that all changing, after a…

Read more »

Businessman hand stacking money coins with virtual percentage icons
Investing Articles

How much second income could investors earn with 9% dividends from Legal & General shares?

Investors looking to build up a second income portfolio have a good few FTSE 100 shares with big dividends to…

Read more »

Rolls-Royce engineer working on an engine
Investing Articles

£5,000 invested in Rolls-Royce shares just 2 years ago is now worth…

Rolls-Royce shares have fallen some way back from a recent 52-week peak, as global events impact them and the firm…

Read more »

Mixed-race female couple enjoying themselves on a walk
Investing Articles

£5,000 invested in Barclays shares just 2 years ago is now worth…

When Barclays shares fall, you've got to ask yourself one question: do you feel... like a long-term investor who just…

Read more »

Portrait of elderly man wearing white denim shirt and glasses looking up with hand on chin. Thoughtful senior entrepreneur, studio shot against grey background.
Investing Articles

Are you ignoring the ISA deadline? Here’s what you may be losing forever!

Think the annual ISA deadline's not your business? You could potentially be missing out, even as a very modest investor.…

Read more »

Aerial shot showing an aircraft shadow flying over an idyllic beach
Investing Articles

How much does someone need to put in the stock market to retire and live off passive income?

Put money in the stock market as a way of building dividend income streams big enough to retire on? Christopher…

Read more »

British flag, Big Ben, Houses of Parliament and British flag composition
Investing Articles

£20k invested in a Stocks and Shares ISA on 7 April could pay this much passive income

Looking for dividend stock ideas in April? Our writer highlights a five-share portfolio that could generate £1,428 a year in…

Read more »

Calendar showing the date of 5th April on desk in a house
Investing Articles

£20,000 in a Stocks and Shares ISA? See how it could be used to target a £989 monthly passive income

Christopher Ruane looks beyond the looming contribution deadline for a Stocks and Shares ISA and takes a long-term approach to…

Read more »